Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...

The results of this comparative effectiveness research study suggest that sodium-glucose cotransporter-2 inhibitors  and glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a ...

A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a ...

New research explores the wide world of the positives, and potential drawbacks, of new obesity medications. And each brings a new consideration for physicians.

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for ...

It's also worth noting that Pfizer has an oral GLP-1 agonist drug in development, danuglipron. Given recent performance, however, we also have to acknowledge the possibility that Pfizer stock ends ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Glucagon-like peptide 1 receptor agonist use was not associated with an increased risk for thyroid cancer compared with use of dipeptidyl peptidase-4 inhibitors. HealthDay News — Glucagon-like peptide ...

Furthermore, the company’s broad obesity pipeline and the upcoming Phase 2 data for its lead GLP agonist, GSBR-1290, are expected to be major catalysts for the stock. The recent success of Novo ...